Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
135 participants
OBSERVATIONAL
2024-08-26
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacogenomics Results Affect Patients' Plan of Care and Changes in Medication Prescription(s)
NCT03322189
Vascular Lifestyle-Intervention and Screening in Pharmacy
NCT02223793
Implementing a Pharmacist-Integrated Collaborative Model of Medication Treatment for Opioid Use Disorder
NCT05310786
Improving Safety by Basic Computerizing Outpatient Prescribing
NCT01091038
Testing the SNOWDROP Intervention: Using a Clinical Decision Support System and Patient Portal for Falls Prevention Among Older Patients in Primary Care
NCT05611008
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The primary objective is to compare the sensitivity, specificity, and accuracy of the Intelligent Fingerprinting Drug Screening System to the validated confirmatory LC-MS/MS technique.
The secondary objectives are to assess drug screening system usability and reproducibility.
"Operators" comprise nine (9) adults: male and female subjects who operate the drug screening system. These subjects are not administered any drug. "Operators" represent end users who utilize the screening system in a laboratory setting. "Operators" will be provided the Intelligent Fingerprinting Drug Screening Guide, Confirmatory Laboratory Analysis Guide, and Quick Reference Guide, and be trained in system use. After receiving and reviewing all materials, the "operator" will complete a Training Exam to determine if he or she may proceed with testing.
"Donors" comprise 135 healthy adults: male and non-pregnant female subjects who provide fingerprint sweat specimens. Subjects will be randomized into the blocks administered 0, 30, or 60mg of codeine sulfate in tablet form. "Donors" represent end users either applying for employment or working at an organization that conducts pre-employment and/or periodic workplace drug screening.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
3
Donors randomized into the 60 mg codeine dosage block
Fingerprint sweat drug screen
Qualitative lateral-flow immunoassay analysis of fingerprint sweat specimen
Fingerprint sweat laboratory analysis
Laboratory analysis of fingerprint sweat specimen by liquid chromatography/tandem mass spectrometry
1
Donors randomized into the 0 mg codeine dosage block
Fingerprint sweat drug screen
Qualitative lateral-flow immunoassay analysis of fingerprint sweat specimen
Fingerprint sweat laboratory analysis
Laboratory analysis of fingerprint sweat specimen by liquid chromatography/tandem mass spectrometry
2
Donors randomized into the 30 mg codeine dosage block
Fingerprint sweat drug screen
Qualitative lateral-flow immunoassay analysis of fingerprint sweat specimen
Fingerprint sweat laboratory analysis
Laboratory analysis of fingerprint sweat specimen by liquid chromatography/tandem mass spectrometry
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fingerprint sweat drug screen
Qualitative lateral-flow immunoassay analysis of fingerprint sweat specimen
Fingerprint sweat laboratory analysis
Laboratory analysis of fingerprint sweat specimen by liquid chromatography/tandem mass spectrometry
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. \*Completed the screening process within 30 days prior to dosing. Subjects screened as a part of an IRB-approved General Screening Protocol at the clinical research site may be included in this study without additional screening procedures, provided all the required screening procedures have been performed within 30 days prior to dosing.
3. Healthy male and non-pregnant female subjects from ages 18 to 65, inclusive, at the time of dosing.
4. \*Body mass index (BMI) from 18 kg/m2 to 30 kg/m2, inclusive, and weigh at least 60 kg.
5. \*Females of childbearing potential must be willing to practice an acceptable form of contraception (see Section 9.3.3), and have a negative urine pregnancy test on admission to the treatment phase of the study.
6. \*Males must agree to practice an acceptable form of contraception.
7. \*Judged by the Investigator and/or designee to be in good health as documented by the medical history, and vital sign assessments. Any abnormalities or deviations outside the normal range for vital signs can be repeated by clinical staff and judged to be not clinically significant for study participation.
Exclusion Criteria
2. \*More than three digits absent from the hands due to congenital or accidental cause(s).
3. \*Reports receiving any investigational drug within 30 days prior to dosing.
4. \*Reports a clinically significant illness during the 30 days prior to the in-clinic portion of the study (as determined by the Investigator).
5. \*Reports any personal history of substance abuse (including drug/alcohol abuse or addiction) or mental illness (e.g. major depression) within one year prior to screening visit.
6. \*Is pregnant (females only).
7. \*Presence of any clinically significant results from laboratory tests and vital signs assessments, as judged by the Investigator.
8. \*Reports history of respiratory depression (e.g., sleep apnea).
9. \*Current severe hypotension (i.e., systolic blood pressure \<90 mmHg).
10. \*Reports known or suspected gastrointestinal obstruction including, paralytic ileus.
11. \*Reports current presence of acute bronchial asthma/ upper airway obstruction.
12. \*Reports a history of clinically significant allergies, including food or drug allergies, as judged by the Investigator.
13. \*Reports history or current condition of adrenal insufficiency.
14. \*Reports history or current condition of renal disease.
15. If, in the opinion of the Investigator, the subject is not suitable for the study.
* Required only for \"donors.\" Not required for \"operators.\"
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Intelligent Bio Solutions Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CenExel iResearch
Decatur, Georgia, United States
CenExel HRI
Berlin, New Jersey, United States
CenExel HRI
Marlton, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Kimball Johnson, MD
Role: backup
Cassie Blanchard, PhD
Role: backup
Elan Cohen, PhD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IBS-2024-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.